News & Announcements
-
US Academic Medical Centre Adopts IB Clinic
/**/ RNS Number : 5033S Imaging Biometrics Limited 28 August 2026 28 August 2026 Imaging Biometrics Limited (“Imaging Biometrics”, the “Company” or, together with its subsidiaries, the “Group”) Major Midwest US Academic Medical Centre Adopts IB Clinic Annual subscription adds to recurring revenue, with a full twelve month contribution in 2027 Imaging Biometrics Limited…
-
Half Yearly Report to 30 June 2026
/**/ RNS Number : 2393O Imaging Biometrics Limited 29 July 2026 29 July 2026 Imaging Biometrics Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2026 The Board of Imaging Biometrics Limited is pleased to announce the Company’s half yearly report for the period ended 30 June 2026.…
-
Sub-division
/**/ RNS Number : 2696M Imaging Biometrics Limited 14 July 2026 Imaging Biometrics Limited (“IBAI” or the “Company”) Sub-division Further to the announcements of 12 May and 3 June, the Company is pleased to confirm that the sub-division has completed with a resulting 246,709,789 ordinary shares of £0.005. The Company has received…
-
Publication of Phase 1 Clinical Trial
/**/ RNS Number : 4746H Imaging Biometrics Limited 09 June 2026 Imaging Biometrics Limited (“Company”) 9 June 2026 Publication of Phase 1 Clinical Trial of Oral Gallium Maltolate (GaM) in Recurrent Glioblastoma and Reopening of Expanded Access Programme Imaging Biometrics Limited (LSE: IBAI) announces the publication in the peer-reviewed journal Neuro-Oncology Advances describing…
-
Commercialisation, Phase II Results & Revenue Path
/**/ RNS Number : 0999H Imaging Biometrics Limited 05 June 2026 IMAGING BIOMETRICS LIMITED (“IBAI” or the “Company”) (LSE: IBAI) 5 June 2026 IB Neuro™ Commercialisation Plan – ASCO 2026 Phase II Results and Strategic Revenue Pathway Imaging Biometrics Limited (LSE: IBAI) is pleased to update shareholders on the EAF151 Phase…